Opinion Meghann Chilcott, chief technology/marketing officer at Benzer Pharmacy provides insights for expanding point-of-care (POC) testing services in the US retail environment, and opportunities for improving patient outcomes and customer satisfaction in the process.   POC testing makes it possible for patients to receive the treatment or the advice they need…

Mexico Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three key reasons why fighting corrupt practices is so important.   The pharmaceutical industry must act according to value-based codes, building…

Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes.   Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…

Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…

Cannabis OPINION: Keith Wolsko and Danielle Moore of cannabis industry recruitment specialists Simply Kind Solutions highlight the seismic recent growth of the USA’s burgeoning cannabis industry and the kinds of profiles that the industry is looking for.   We are witnessing the birth of the next great American industry. So, you…

USA As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap…

Opinion Jan Hux, the president and CEO of Diabetes Canada calls for governments to place greater importance on partnerships with patient groups for the making of big decisions in healthcare.    The establishment of a multi-stakeholder group, including patient organizations and patient representatives, could provide feedback and public policy recommendations to…

Opinion Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare disease patients and well-designed clinical trials are also essential to evaluating new therapeutics. In this article, PJ Brooks, Program Director at the Office of Rare…

Opinion On International Women’s Day 2019, David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made to close the gender investment gap, touching on key trends and biases in venture capital funding and outlining why investing in women matters.   When women business owners pitch their…

Opinion Robin Toft is the Author of WE CAN™, the Executive Woman’s Guide to Career Advancement and founder and CEO of Toft Group Executive Search, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. In this article, she discusses the…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve unemployment rates in Mexico and how the pharmaceutical industry is getting involved.    The investment in human capital is an…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…